More recently, EDI3 was additionally reported by other groups to play a role in hypoxia-induced mitophagy in triple-negative breast cancer [28], and with sunitinib and paclitaxel resistance in renal and ovarian cancer, respectively [29, 30]. Here, GPCPD1 is linked to ovarian carcinoma.